Details

Evdoksova hipopeda : študijsko gradivo : zgodovina matematike
ID Razpet, Marko (Author)

.pdfPDF - Presentation file, Download (1,91 MB)
MD5: 427907366588B003D1ADBB288D056DB0

Language:Slovenian
Typology:2.05 - Other Educational Material
Organization:PEF - Faculty of Education
Place of publishing:Ljubljana
Publisher:Univerza v Ljubljani, Pedagoška fakulteta, Oddelek za matematiko in računalništvo
Year:2013
Number of pages:46 str.
PID:20.500.12556/RUL-17484 This link opens in a new window
UDC:51
COBISS.SI-ID:9665353 This link opens in a new window
Publication date in RUL:11.07.2014
Views:11549
Downloads:268
Metadata:XML DC-XML DC-RDF
:
RAZPET, Marko, 2013, Evdoksova hipopeda : študijsko gradivo : zgodovina matematike [online]. Other Educational Material. Ljubljana : Univerza v Ljubljani, Pedagoška fakulteta, Oddelek za matematiko in računalništvo. [Accessed 24 July 2025]. Retrieved from: https://repozitorij.uni-lj.si/IzpisGradiva.php?lang=eng&id=17484
Copy citation
Share:Bookmark and Share

Similar documents

Similar works from RUL:
  1. Pomen tumorskih matičnih celic in epitelno-mezenhimskega prehoda pri napredovanju nedrobnoceličnega raka pljuč
  2. Gene expression levels of the prolyl hydroxylase domain proteins PHD1 and PHD2 but not PHD3 are decreased in primary tumours and correlate with poor prognosis of patients with surgically resected non-small-cell lung cancer
  3. Proučevanje izražanja gena za fosfatidiletanolamin-N-metiltransferazo v nedrobnoceličnem pljučnem rakavem tkivu
  4. Uporabnost imunohistokemičnega določanja mutacij receptorja za epidermalni rastni faktor pri raku pljuč
  5. Sladkorna bolezen in športna vadba
Similar works from other Slovenian collections:
  1. Expression patterns and prognostic relevance of subtype-specific transcription factors in surgically resected small cell lung cancer
  2. Outsourcing predictive biomarker testing in non-small cell carcinoma
  3. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  4. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer
  5. NSCLC molecular testing in Central and Eastern European countries

Back